Adjuvance Technologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2009-07-08
- Employees
- 11
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Pertussis Acellular Vaccine Adjuvanted With TQL1055
Phase 1
Terminated
- Conditions
- Pertussis
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Adjuvance Technologies, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04793620
- Locations
- 🇦🇺
Q-Pharm, Brisbane, Australia
News
No news found